Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 12,248 people enrolled
- Started
- 18 Feb 2022
- Ended
- 7 May 2025
- Type of study
- Interventional
- Treatments tested
- Sugammadex 100 MG/ML [Bridion]
- Record updated
- 29 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- UCLA Ronald Reagan or Santa Monica patients aged 18 and older who had a general anesthetic with either rocuronium or vecuronium
- Patients who receive sugammadex from the specified study supply
Who cannot take part
- Patients who remain intubated after surgery or leave the operating room with a tracheostomy in-situ
- Patients with known hypersensitivity to any of the following: rocuronium, vecuronium, sugammadex, neostigmine or glycopyrrolate
- Patients with known neuromuscular disease
- Patients under the age of 18
- Patients with a preoperative glomerular filtration rate less than 30 or on hemodialysis
- Patients who did not receive reversal of neuromuscular blockade (with neostigmine in the pre-period or sugammadex in the post-period)
Where in United States
- Ronald Reagan UCLA Medical CenterLos Angeles, United States
About the trial
What the trial wants to find out
The purpose of this study is to:
Read full original descriptionShow less
1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after the introduction of sugammadex into clinical practice. 2. Develop and implement a clinical best practice pathway designed to prevent postoperative respiratory complications in higher risk patients (such as those with OSA or preexisting respiratory disease) using education and clinical decision support in patients.
The group in the trial
- CDS pathwayTreatment being tested
When the anesthesiologist completes the preoperative evaluation for a patient who is flagged as having either respiratory disease or OSA and will receive general anesthesia, the anesthesiologist will receive a pop-up window reminding them of the best practice guidelines for pulmonary management in high-risk patients. We anticipate that the pathway will suggest 1) use of sugammadex to reverse neuromuscular blockade if rocuronium was used 2) use of objective train of four monitoring throughout the case and to confirm reversal 3) use of a tidal volume of 6-8 cc/kg 4) use of at least 5 cmH2O of PEEP
Treatment: Sugammadex 100 MG/ML [Bridion]
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Digital Quality Improvement Project to Apply Best Clinical Practices to Patients at High Risk of Respiratory Complications
- Record updated
- 29 July 2025